US008821915B2

(12) **United States Patent**
Cincotta

(10) **Patent No.: US 8,821,915 B2**
(45) **Date of Patent: *Sep. 2, 2014**

(54) **THERAPEUTIC PROCESS FOR THE TREATMENT OF THE METABOLIC SYNDROME AND ASSOCIATED METABOLIC DISORDERS**

(75) Inventor: **Anthony Cincotta**, Tiverton, RI (US)

(73) Assignee: **VeroScience, LLC**, Tiverton, RI (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/200,127**

(22) Filed: **Sep. 19, 2011**

(65) **Prior Publication Data**

US 2012/0129783 A1 May 24, 2012

Related U.S. Application Data

(63) Continuation-in-part of application No. 10/944,617, filed on Sep. 17, 2004, now Pat. No. 8,021,681, which is a continuation-in-part of application No. 10/635,841, filed on Aug. 6, 2003, now abandoned.

(60) Provisional application No. 60/402,231, filed on Aug. 9, 2002.

(51) **Int. Cl.**

A61K 47/00	(2006.01)
A61K 31/70	(2006.01)
A61K 31/40	(2006.01)
A23L 1/29	(2006.01)
A61K 31/198	(2006.01)

(52) **U.S. Cl.**

CPC ***A23L 1/293*** (2013.01); ***A23L 1/296*** (2013.01); ***A61K 31/198*** (2013.01)

USPC **424/439**; 514/23; 514/419

(58) **Field of Classification Search**

USPC 424/439; 514/23, 419

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,009,265	A *	2/1977	Howard	514/4.8
4,338,304	A	7/1982	Kamimae et al.	424/669
4,446,138	A *	5/1984	Pack	514/235.2
4,659,715	A	4/1987	Meier et al.	A61K 31/44
4,749,709	A	6/1988	Meier et al.	A61K 31/44
4,783,369	A	11/1988	Sugata et al.	
4,971,969	A	11/1990	Carlier et al.	A61K 31/495
5,006,526	A	4/1991	Meier et al.	A61K 31/495
5,344,832	A	9/1994	Cincotta et al.	A61K 31/44
5,468,755	A	11/1995	Cincotta et al.	A61K 31/44
5,585,347	A	12/1996	Meier et al.	A61K 38/00
5,741,503	A	4/1998	Cincotta et al.	
5,744,477	A	4/1998	Cincotta et al.	A61K 31/44
5,760,047	A	6/1998	Cincotta et al.	A61K 31/44
5,877,183	A	3/1999	Cincotta	A61K 31/44
6,004,972	A	12/1999	Cincotta et al.	A61K 31/44
6,011,049	A *	1/2000	Whitcomb	514/369
6,040,292	A	3/2000	Sommer	A61K 38/00
6,166,017	A	12/2000	Marin	A61K 31/50
6,197,765	B1	3/2001	Vardi et al.	A61K 31/5415
6,248,375	B1 *	6/2001	Gilles et al.	426/72
6,365,176	B1 *	4/2002	Bell et al.	424/439
6,376,464	B1	4/2002	Dasseux et al.	A61K 38/00
6,410,339	B1	6/2002	Marin	G01N 33/53
6,441,036	B1	8/2002	Berge	A01N 37/02
6,506,799	B1	1/2003	Dasseux	A61K 31/075
2001/0002269	A1 *	5/2001	Zhao	426/112

FOREIGN PATENT DOCUMENTS

EP	1 004 594 A1	5/2000	
WO	WO 96/39050	12/1996	A23L 1/29
WO	WO 96/39052	12/1996	A23L 1/30
WO	WO 96/39868	12/1996	A23L 1/29

OTHER PUBLICATIONS

Nielsen et al (Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 300, Summary; 1977).

NIH Publication No. 5-4642 [online], www.diabetes.niddk.nih.gov, Jan. 2005 [retrieved on Jun. 11, 2008]. Internet: <URL: http://diabetes.niddk.nih.gov/dm/pubs/diagnos is/.

Freedman, Marjorie R., King, Janet, and Kennedy, Eileen, "Popular Diets: A Scientific Review", Obesity Research, vol. 9, Supp. 1, pp. 1S-40S (Mar. 2001).

Baba, N. Hwalla, et al., "High protein vs high carbohydrate hypoenergetic diet for the treatment of obese hyperinsulinemic subjects", International Journal of Obesity, vol. 23, pp. 1202-I206 (Nov. 1999).

Alford, B. B., et al., "The effects of variations in carbohydrate, protein, and fat content of the diet upon weight loss, blood values, and nutrient intake of adult obese women", Journal of the American Dietetic Association, vol. 90, No. 4, pp. 435-540 (Apr. 1990).

* cited by examiner

Primary Examiner — Kevin E Weddington

(74) *Attorney, Agent, or Firm* — Fish & Richardson P.C.

(57) **ABSTRACT**

The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens.

11 Claims, No Drawings